#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.
Dr. Peter Attia and psychiatrist Dr. Linus Abrams explore how mental health extends beyond neurotransmitters, integrating hormones, metabolism, inflammation, and circadian biology. They discuss psychiatric medications, the importance of bipolar diagnosis, and the profound impact of hormones like estrogen, progesterone, testosterone, and thyroid on mood and cognition.
Deep Dive Analysis
17 Topic Outline
Dr. Abrams' Pivot to Integrative Psychiatry
Critique of Symptom Reduction vs. Full Human Experience
The Unique Nature of Psychiatric Diagnosis
Primer on Psychotropic Drug Classes: SSRIs and SNRIs
Understanding Bipolar Disorder vs. Unipolar Depression
Evolutionary Perspectives on Depression and Anxiety
Modern World Factors Impacting Mental Health
Foundational Biological Factors and Distress Tolerance
The Role of Estradiol in Brain Function
Testosterone's Impact on Male Mood and Cognition
Progesterone's Role in PMDD and Postpartum Depression
Diagnosing and Treating Hypothyroidism as Depression
Addressing Chronic Hyperarousal and Cortisol
Bipolar Disorder Unmasked by Menopause Transition
Ketamine for Treatment-Resistant Depression
Psychedelics: Promise, Risks, and Personal Experiences
Future of Psychedelic Therapies in Psychiatry
9 Key Concepts
Psychopharmacology
The study and use of medications that affect the mind, emotions, and behavior, historically focused on modulating neurotransmitters like serotonin, dopamine, and norepinephrine.
SSRIs (Selective Serotonin Reuptake Inhibitors)
A class of psychotropic drugs that primarily target serotonin, modulating its neurotransmission by amplifying its signal. They are often used for anxiety and depression, but can sometimes lead to blunting or decreased dopamine.
SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors)
A class of psychotropic drugs that balance effects on both serotonin and norepinephrine reuptake. They may be less likely to cause cognitive dulling or affective blunting compared to pure SSRIs.
Dysthymic Disorder
A chronic, low-grade depressive tendency characterized by persistent low mood, pessimism, irritability, and lack of optimism. It differs from a major depressive episode, which has a bigger amplitude but typically lower frequency.
Bipolar 2 Disorder
A common form of bipolar disorder where the elevated mood component is hypomania (less severe than full mania) and can be adaptive. However, the depressive phases respond differently to antidepressants than unipolar depression.
Allopregnanolone
A neurosteroid derivative of progesterone that significantly drops toward the end of the luteal phase. This rapid fall can contribute to conditions like Premenstrual Dysphoric Disorder (PMDD) and postpartum depression in susceptible women.
NMDA Receptor Antagonist
A type of drug, like ketamine, that blocks NMDA receptors, leading to a massive release of glutamate, protein synthesis, and synaptic remodeling. This results in sudden, dramatic neuroplasticity, which can rapidly alleviate suicidal ideation.
Neuroplasticity
The brain's ability to reorganize itself by forming new neural connections throughout life. This process can be influenced by hormones (e.g., estradiol) and certain medications (e.g., ketamine, psychedelics), offering therapeutic potential for mental health conditions.
REBUS Model (Relaxed Belief Under Psychedelics)
A model suggesting that psychedelics induce a state of 'relaxed belief,' promoting neuroplasticity that allows for the adjustment of maladaptive prior beliefs. This therapeutic window can facilitate significant change in individuals with depression and anxiety disorders.
8 Questions Answered
Patients often perceive psychopharmacological interventions as undesirable, even when objectively successful, because they aim at symptom reduction but not the restoration of the full human experience that makes life worthwhile.
SSRIs primarily target serotonin reuptake, while SNRIs target both serotonin and norepinephrine reuptake. Raising serotonin with SSRIs can decrease dopamine, potentially leading to a blunted feeling, which SNRIs may mitigate by balancing neurotransmitter effects.
Bipolar depression responds differently to antidepressants; prescribing an antidepressant alone can trigger mood cycling, hypomania, or mixed states, whereas a mood stabilizer is often the correct first-line treatment to prevent these adverse shifts.
Estradiol is a profound multi-system regulator of neurotransmitters (serotonin, dopamine, GABA, acetylcholine, glutamate) and neural circuits. It influences mood regulation, cognition, and anxiety by creating the conditions for neurotransmission and affecting gene transcription.
It's not the low level itself, but the significant fluctuation and rapid fall of progesterone (and its derivative allopregnanolone) from high levels that can trigger severe mood and cognitive symptoms in susceptible women due to biological factors like receptor morphology and genetics.
Hypothyroidism (low thyroid) can present as depression, even with TSH levels in the 'normal' range. Diagnosis often relies more on suboptimal free T4 and free T3 levels, as TSH only indicates what the pituitary thinks of the thyroid axis.
Ketamine acts as an NMDA receptor antagonist, leading to a massive release of glutamate and rapid neuroplasticity, which can quickly dissipate suicidal risk. However, its antidepressant effects are often temporary, requiring further treatment to find a lasting solution.
Psychedelics can induce profound neuroplasticity and therapeutic windows for addressing maladaptive beliefs, offering durable positive effects for conditions like end-of-life depression or PTSD. However, they also carry risks of unpredictable and potentially devastating negative experiences.
12 Actionable Insights
1. Prioritize Full Human Experience
Aim for psychiatric care that not only reduces symptoms but also restores the full human experience, focusing on vitality and well-being beyond just symptom absence, as patients often feel medication is undesirable even when effective.
2. Recognize Bipolar Depression Differences
Be aware that bipolar depression responds differently to antidepressants than unipolar depression; antidepressants can trigger mood cycling, hypomania, or mixed states in bipolar individuals, making correct diagnosis crucial.
3. Stabilize Bipolar Depression First
For bipolar depression, initiate pharmacotherapy with a mood stabilizer (e.g., lamotrigine or lithium) before considering antidepressants, as this approach is less likely to induce hypomania or mixed states.
4. Address Foundational Biological Factors
Recognize that mental health is deeply influenced by foundational biological factors like nutrition, exercise, sleep, and endocrine function, which are often challenged by modern life and require deliberate management.
5. Widen Your Distress Tolerance Window
Understand that irritability and distress tolerance are significantly impacted by biological factors (exercise, sleep, pain, stress); actively manage these to increase your capacity to handle life’s challenges and improve mood.
6. Consider Hormonal Impact on Mood
For women, recognize that fluctuations and reductions in estradiol and progesterone (e.g., during perimenopause, menopause, or postpartum) can profoundly impact mood, cognition, and anxiety due to their role in neurotransmitter modulation.
7. Evaluate Testosterone for Male Mood/Cognition
For men experiencing dullness, loss of drive, or ADHD-like symptoms, consider declining testosterone levels, as testosterone modulates dopamine-mediated functions related to reward and executive function.
8. Avoid Clomiphene for Testosterone Replacement
While Clomiphene can increase testosterone numbers in the periphery, it often fails to alleviate symptoms and may interfere with central estrogen/testosterone signaling, making exogenous testosterone a superior option for symptom relief.
9. Assess Thyroid for Depression
If experiencing depression, especially with ’normal’ TSH but suboptimal free T4, consider thyroid hormone supplementation, as low thyroid can manifest as depression and impact metabolism and neurotransmitter receptor density.
10. Address Chronic Hyperarousal at Source
If experiencing chronic hyperarousal (high cortisol), identify and address the root causes of stress (e.g., caregiving burdens, occupational stress) rather than solely focusing on the cortisol as the primary problem.
11. Approach Psychedelics with Caution
Understand that psychedelic therapies like psilocybin and ketamine can have profound, sometimes unpredictable, effects; while potentially transformative, they carry risks and require careful consideration and supervision due to their potent neuroplasticity.
12. Peel Back Medication Layers Slowly
When a patient is feeling good on a complex medication regimen, gradually try to taper off agents in order of efficacy, allowing for a more minimalistic approach once stability is achieved.
5 Key Quotes
Psychiatry aims at reduction of symptoms, but not restoration of the full human experience that makes life most worthwhile.
Dr. Linus Abrams
Understanding the patient is always greater than my ability or any provider... to understand them. Because the nature of a human being is so unique and remarkable.
Dr. Linus Abrams
Estradiol is a constitutive pleiotropic multi-system regulator of neurotransmitters and neural circuits.
Dr. Linus Abrams
Hormones were evolved by the brain for the brain.
Dr. Linus Abrams
It's extraordinary that a single administration of a drug can produce a durable effect that you're projecting will last a lifetime.
Dr. Linus Abrams
2 Protocols
Initiating Pharmacotherapy for Bipolar Depression
Dr. Linus Abrams- Start with a mood stabilizer (e.g., lamotrigine or lithium) as monotherapy.
- If monotherapy is insufficient, consider adding an antidepressant, as the mood stabilizer provides a 'ceiling effect' against mood elevation and a 'floor effect' against further depression.
- Titrate based on patient response and symptom improvement.
T3 Supplementation for Treatment-Resistant Depression
Dr. Linus Abrams- Start with a low dose of immediate-release T3 (e.g., 2.5 micrograms) twice a day.
- Administer the first dose in the morning and the second 6-8 hours later, avoiding late administration to prevent insomnia.
- Titrate dosage based on symptom relief, blood pressure, and pulse, potentially increasing up to 25 micrograms twice a day.